Gold prices steady ahead of Fed decision; weekly weakness noted
On Friday, Stifel analysts maintained their Buy rating and $25.00 price target for Evolus (NASDAQ:EOLS), currently trading at $9.34, following a series of meetings with the company’s management and key opinion leaders (KOLs) in the aesthetics industry. According to InvestingPro data, analyst targets range from $20 to $27, suggesting significant upside potential. The discussions centered around Evolus’s transition from focusing on a single product to developing a broader portfolio of aesthetic treatments.
Evolus CEO David Moatazedi and CFO Sandra Beaver, who is soon departing for a new opportunity, outlined the company’s strategy for launching its Evolysse fillers, named SMOOTH and FORM. These products are part of Evolus’s journey towards achieving non-GAAP operating profitability, with the company currently maintaining a healthy gross margin of 68.41% and a strong current ratio of 2.34. The company has also refinanced its credit facility, which is expected to provide greater capital flexibility for future business development activities.
During a separate KOL dinner, the state of the injectable market was examined, with particular attention to the potential for market disruption. Despite prevailing macroeconomic uncertainties, the underlying demand for injectables appears to remain robust. KOLs indicated that there has been no noticeable slowdown in procedures, and growth rates are thought to be stronger than general market indicators suggest. The sentiment was that company and product-specific trends are more influential than broader economic factors.
According to Stifel’s analysis, Evolus is positioned to continue performing well in the market, thanks to a balance of product quality and high-touch service that resonates with customers. The firm’s confidence in Evolus’s market strategy and product pipeline is reflected in the reiterated Buy rating and price target, signaling a positive outlook for the company’s stock.
In other recent news, Evolus Inc . reported a larger-than-expected loss for Q1 2025, with an EPS of -$0.30, missing the forecast of -$0.09. Despite this, the company’s revenue grew by 15.5% year-over-year to $68.5 million, although it fell short of the $72.51 million forecast. Evolus has reaffirmed its full-year revenue guidance, expecting between $345 million and $355 million, and anticipates reaching $700 million in net revenue by 2028. Meanwhile, Mizuho (NYSE:MFG) Securities maintained its Outperform rating on Evolus, with a price target of $25, expressing confidence in the company’s growth trajectory. This rating comes amidst the announcement of CFO Sandra Beaver’s resignation to join Lyra Health, with Evolus actively searching for her successor. Additionally, a clinical study published in the Aesthetic Surgery Journal highlighted the effectiveness of Evolysse HA gels, which outperformed Restylane in treating facial wrinkles. The company also announced its plans for a broader European launch of its HA gels under the brand name Estyme® in the second half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.